MOG antibody-associated disease is typically understood as an autoimmune disorder in which antibodies target myelin oligodendrocyte glycoprotein, producing demyelination and relapsing neurological symptoms. This antibody-centered model has been clinically useful, but it may be incomplete in explaining why disease expression varies so widely between individuals, why some patients recover remarkably well between attacks, and why similar immunologic profiles can lead to very different trajectories over time. In my independent conceptual synthesis, I propose that MOGAD is better understood as a multi-layer instability system in which immune activity is not the sole initiating force but one visible output of deeper interacting biological thresholds involving oligodendrocyte resilience, metabolic conduction capacity, neuroimmune interface behavior, and systemic immune architecture.
At the foundation of this model is the idea that oligodendrocytes are not uniformly vulnerable across individuals. Instead, there may be intrinsic heterogeneity in their resilience, shaped by genetic, developmental, and epigenetic influences. Under this view, susceptibility to immune-mediated injury is not determined exclusively by the presence of autoreactive immune elements but also by the biological state of the target cells themselves. Oligodendrocytes under metabolic stress or altered signaling conditions may become more visible or more susceptible to immune recognition, potentially lowering the threshold for autoimmune engagement. This reframes disease susceptibility as a dynamic interaction between immune surveillance and cell-intrinsic vulnerability rather than a unidirectional immune attack on a passive target.
Building on this, transient neurological phenomena such as heat-induced symptom worsening, often described clinically as Uhthoff’s phenomenon, may represent more than symptomatic variability. Instead, they may function as a real-time indicator of conduction instability in partially demyelinated axons. When physiological demand increases, such as during heat exposure or exertion, energy requirements for axonal conduction rise. In regions where myelin integrity is compromised, ion channel redistribution and mitochondrial inefficiency may push neuronal signaling past a reversible threshold. This produces functional impairment that is not necessarily structural damage but rather a manifestation of metabolic and electrical fragility.
Extending beyond the axon and oligodendrocyte unit, the neuroimmune interface introduces additional layers of complexity. Microglia, astrocytes, and the blood-brain barrier do not merely respond to inflammation but actively shape it. Microglia may remain in a primed state following prior inflammatory or infectious exposures, maintaining heightened responsiveness long after peripheral immune activity appears normalized. The blood-brain barrier may exhibit transient permeability changes that allow episodic immune access to central nervous system antigens. Astrocytes further regulate glutamate balance and metabolic coupling, influencing whether neural tissue remains stable or shifts toward inflammatory sensitization.
In parallel, the peripheral immune system contributes structural memory beyond measurable antibody levels. T-cell receptor repertoires, B-cell memory niches, and regulatory T-cell stability collectively shape immune baseline behavior. Even in remission, deeper immune architecture may preserve autoreactive bias. Thus, disease expression may reflect not only circulating immune factors but also an underlying immune set point.
Within this framework, autologous hematopoietic stem cell transplantation (AHSCT) may be understood not simply as immune suppression but as partial immune system reprogramming. By depleting autoreactive immune clones and rebuilding immune populations from hematopoietic stem cells, AHSCT may restore aspects of central tolerance and shift immune dynamics toward a more naive and regulated state. However, variability in outcomes suggests that immune reset alone may not fully address CNS-resident immune memory or glial vulnerability states.
When these layers are considered together, MOGAD emerges not as a linear disease process but as a dynamic system governed by interacting thresholds. Oligodendrocyte vulnerability establishes baseline susceptibility, metabolic and conduction stability determines functional reversibility, neuroimmune interface behavior modulates inflammatory amplification, peripheral immune architecture shapes systemic bias, and immune resetting interventions may partially restore equilibrium. Disease activity becomes a state transition across biological systems rather than simple lesion accumulation.
This model generates several testable implications, including cellular profiling of oligodendrocyte heterogeneity, functional stress testing of conduction stability, immune repertoire sequencing across disease phases, and imaging-based markers of reversible versus irreversible tissue dysfunction. These approaches may help distinguish static injury from dynamic biological instability.
The broader implication is a shift from lesion-centered thinking toward systems-level neuroimmunology in which disease is defined by transitions between states of resilience and instability rather than irreversible damage alone.
This hypothesis is offered as a conceptual framework for critique, refinement, and empirical testing in neuroimmunology and translational neuroscience.
Josette Pelatan is a medical researcher.
